

BUSINESS

 $\overrightarrow{}$

Marijuana M&A boom awaits, in California and beyond



After a financial drought for even some of the biggest multistate players, activity is heating up in the marijuana market just as the march toward U.S. legalization — at both the state and federal levels — picks up pace, creating a perfect environment for an M&A boom. (Associated Press)

By TIFFANY KARY | BLOOMBERG FEB. 7, 2021 5:05 PM PT

Jazz Pharmaceuticals' \$7.2-billion purchase of GW Pharmaceuticals last week is the biggest tie-up yet for the cannabis industry. And it's probably just the beginning.


The blockbuster <u>deal</u>, which dwarfs Tilray Inc. and Aphria Inc.'s \$3.8billion merger as well as Constellation Brands Inc.'s multibillion-dollar <u>investment</u> in Canopy Growth Corp., shows the growing interest in pharmaceutical-grade cannabinoids. With big money flowing into this market and the broader industry, it also portends more major deals ahead.

CORONAVIRUS AND PANDEMIC > As alcohol abuse rises amid pandemic, hospitals see a wave of deadly liver disease Her COVID-19 treatment cost more than \$1 million. Who's going to pay for it? South Africa's coronavirus strain upends country's vaccination plans Some California churches reopen after Supreme Court lifts ban on indoor services Tracking ICU capacity in California Cases statewide » 3,395,017 44,153 confirmed deaths As of February 7, 10:35 p.m. Pacific



"Capital is back in the cannabis sector," Bill Doran, a partner in Benesch's Chicago office specializing in mergers and acquisitions, said last week.

After a financial drought for even some of the biggest multistate players, activity is heating up just as the march toward U.S. legalization — at both the state and federal levels — picks up pace, creating a perfect environment for an M&A boom. The big question now is where those deals are likely to happen.



Doran predicts California will be a key. Despite being difficult to evaluate because of the persistence of the black market, there are a lot of small, promising brands with loyal followings.

"Multistate operators that aren't there already will set their sights on California," he said. "It's by far the biggest market in the country, and it eclipses the entire Canadian market from a demand perspective."

States that have medical markets but haven't yet legalized recreational use will also continue to attract companies that want to get in before the legal change, he said, citing Cresco Labs' recent \$213-million deal with Bluma Wellness to move into Florida.

Investors will also look to ancillary technologies that support the industry, such as logistics companies and e-commerce specialists. Think Uber-Drizly's <u>alcohol-delivery deal</u>, but for cannabis. Again, California is a ripe geography for acquisitions because cannabis has been legal for longer there, giving it a more developed market. PLUMBING-SEWER-HEATING-COOLING-ELECTRIC IL 055-013536 SCHEDULE NOW 4abc.com

LATEST BUSINESS >

BUSINESS

Koji can help you sell to your social media followers Feb. 6, 2021

HOT PROPERTY

Home of the Week: A Tuscan-inspired retreat in the Palisades

Feb. 6, 2021

BUSINESS

S&P 500 climbs again, closing out best week since November

Feb. 5, 2021

BUSINESS

Column: How often have tax cuts for the rich trickled down to the rest of us? Never Feb. 5, 2021

BUSINESS

Plane, train, bus passengers without masks now face fines up to \$1,500 Feb. 5, 2021

ADVERTISEMENT

Although there are hundreds of smaller players that may be eager to pair

off, economics favor companies with more scale, said Matt Hawkins, managing partner of private equity firm Entourage Effect Capital.

"Companies that are larger and can move quickly to sell to institutional capital or large CPG, alcohol, pharmaceutical, nutraceutical and tobacco companies are going to be the ones the market rewards first," Hawkins said. His firm has deployed more than \$150 million in about 66 investments in the cannabis industry.

One of the most interesting factors to watch in this consolidation is the science. A growing number of companies are pursuing research on the compounds in marijuana plants and their effects on specific diseases and disorders.

That was a central factor in the GW-Jazz deal. GW makes an epilepsy medication called Epidiolex, the first drug derived from the cannabis plant to win approval from the U.S. Food and Drug Administration. But it wasn't just about Epidiolex — it was also about the promise of its late-stage trials for other cannabis-derived compounds to treat things such as multiple sclerosis, autism and schizophrenia.

ADVERTISEMENT

Pharmaceutical companies aren't the only ones interested in rare cannabinoids, which can be extracted from plants or synthesized from labs, and usually come without psychoactive effects. In a recent overview of players in that space, ATB Capital Markets analyst David Kideckel said the market, already worth around \$20 billion, is also attractive to consumer companies.

Cannabinoids are likely to become a crucial ingredient in pharmaceuticals and consumer goods, he wrote. With that in mind, the GW deal is a "game changer for the industry."

BUSINESS

= Your guide to our new economic reality.

Get our free business newsletter for insights and tips for getting by.

Enter email address SIGN ME UP

You may occasionally receive promotional content from the Los Angeles Times.

Tiffany Kary

MORE FROM THE LOS ANGELES TIMES

HOT PROPERTY

'FBI' star Jeremy Sisto sells a half-built home in Laurel Canyon 36 minutes ago

WORLD & NATION

Yellen: Biden's plan could restore full employment by 2022 Feb. 7, 2021

WORLD & NATION

South Africa suspends AstraZeneca vaccine drive after study shows minimal protection

Feb. 7, 2021

HOT PROPERTY

Hot Property: Sylvester Stallone lists Beverly Park trophy estate for \$110 million

Feb. 6, 2021

Los Angeles Times

A California Times Publication

Subscribe for unlimited access

Follow Us



eNewspaper	Crossword	About/Contact
Coupons	Sudoku	For the Record
Find/Post Jobs	Obituaries	L.A. Times Careers
Place an Ad	Podcasts	Manage Subscription
Media Kit: Why the L. A. Times?	Recipes	Reprints and Permissions
Bestcovery	Wine Club	Site Map